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Background: The prevalence of mitral regurgitation in cardiac diseases requires annuloplasty systems that can be
implanted without excessive patient burden. This study was designed to examine the morphological and functional
outcome of a new double helix mitral annuloplasty ring in an ovine model in comparison to the classical
Carpentier-Edwards (CE) annuloplasty ring as measured by reduction of mitral regurgitation and tissue integration.
The Medtentia annuloplasty ring (MAR) is a helical device that is rotated into the annulus self-restoring the valve
geometry, enabling a faster fixation without the need of elaborate repair of the valve geometry. The ventricular part
of the helical ring encircles the valve chords.
Methods: Twenty adult sheep were overpaced until 2+ level mitral valve regurgitation was achieved. Seven
animals per group received either the MAR or the CE ring. Implantation was performed on-pump in a beating heart
through the left atrial appendix. The animals were sacrificed 3.6 ± 0.3 months after surgery following an
echocardiography for assessing mitral regurgitation as primary endpoint. The annuloplasty rings with surrounding
tissue were harvested for histological analyses as secondary endpoints. The remaining six sheep received the MAR
system and were sampled seven, nine or 12 months after surgery.
Results: Implantation time (p < 0.01) and perfusion time (p < 0.001) as clinical secondary endpoints were
significantly shorter in the MAR group. Echocardiography follow-ups showed sufficient valve function repair in
nearly all animals with a normalization of the ventricle diameters in both groups (group difference: p = 0.147). The
weights of the hearts did not differ significantly. Histology revealed adequately covered atrial annuloplasty rings
with functional endothelium and lack of excessive granulation tissue or fibrosis in all specimens. The ventricular
projections of the MAR systems encircling the chordae tendineae were not completely covered with neointimal
tissue, although in no case were microthrombi detected and no thromboembolic events were recorded.
Conclusions: The new MAR system is an easy to use annuloplasty system with a functional outcome comparable
to that of the well–proven CE ring. Mitral valve regurgitation is effectively stopped both by restricting the
pathological expansion of the annulus and by gathering the chords without thrombus formation.
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Figure 1 The Medtentia annuloplasty ring. The atrial helix arm is
covered by a cuff, the ventricular part is uncovered. The carbonated
titanium surface effectively prevents cell adhesion and clotting.
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The prevalence both of heart valve and cardiovascu-
lar disease is expected to increase in the next de-
cades. Recent years have witnessed a clear trend
toward a lower level of invasiveness in medical pro-
cedures in general, and in cardiac procedures in par-
ticular [1]. Ischemic mitral regurgitation (IMR), a
consequence of left ventricular dysfunction despite a
structurally normal mitral valve, occurs in 19% of pa-
tients after myocardial infarction [2]. Chronic IMR is
an independent predictor of mortality with a clear
correlation to the degree of mitral regurgitation
(MR): the greater the degree of MR, the worse the
prognosis [3,4].
The repair of mitral and tricuspid incompetence
with preservation of the native valve is a major target
of modern valve surgery [5,6]. The dilatation of the
annulus aggravates regurgitation and thus the im-
plantation of a support prosthesis on the dilated an-
nulus - similar to an annuloplasty ring - is frequently
performed to reconstitute its physiological size and
shape [5].
To further facilitate faster and easier mitral valve
annuloplasty procedures with reduced clamp time, the
novel Medtentia double helix mitral annuloplasty ring
(MAR) was developed [7]. This ring consists of a
double helix similar to a key ring and is implanted by
rotating it around the mitral valve leaflets to place
one helix arm in the left atrium and the other in the
left ventricle (Figure 1). Thus, there is no need for
elaborate and time consuming valve repair before fix-
ation of the MAR. This unique feature potentially al-
lows the consideration and development of a variety
of different fixation methods that might facilitate eas-
ier, minimally invasive approaches. In addition, the
ring fixation is potentially more stable compared to
rings that are only placed in the atrium, such that
the risk of late ring dehiscence may potentially be
reduced.
The most critical aspect is that the exposure of
annuloplasty rings to blood may induce thrombosis and/
or thromboembolism resulting from the adhesion of
fibrin and platelets on the artificial tissue and inflamma-
tory reaction [8]. Local healing with foreign body reac-
tion is a normal consequence of synthetic material
implantation and leads to the formation of fibrous tissue
composed of fibroblasts, foreign body giant cells and
extracellular matrix [5].
The aim of this study in mitral insufficient sheep was
therefore to elucidate the morphological and functional
outcome of the Medtentia double helix mitral annulo-
plasty ring in comparison to the classical Carpentier-
Edwards (CE) Physio Annuloplasty ring in sheep with
mitral valve insufficiency.Methods
Animals
In total, 20 female sheep weighing between 46 and 60 kg
(mean 51 ± 6 kg) were used for this study. The sheep
were obtained from a specialized sheep breeding farm
(Kotikoski, Finland), and were kept in group boxes with
unlimited access to standard food and water in the cen-
tral animal facilities of the Veterinary Medicine Faculty
of Helsinki University hospital. Surgery, final ultrasound
examination, as well as tissue harvesting were performed
either in the animal facilities of Helsinki University Hos-
pital or at the Helsinki University Veterinary Medicine
Faculty. All experiments were carried out in accordance
with the regulations laid down by law after approval of
the local institutional review board (approval no. ESLH-
2008-008641/m-23 and ESLH-2009-066994/m-23).
Rapid ventricular pacing
Pacemakers were used to induce mitral valve insuffi-
ciency with significant 2+ regurgitation. Pilot studies re-
vealed that higher grades of mitral regurgitation resulted
in unacceptably high lethalities for this long term follow-
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(Relia S01, Medtronic Finland, Helsinki) were implanted
and programmed to a continuous frequency of 170/min.
In the first five animals of the series Vitatron C20 pace-
makers (Medtronic Finland, Helsinki) were initially im-
planted, but had to be replaced after failing to induce
mitral valve insufficiency. One day to two weeks before
the annuloplasty ring implantation, the frequencies were
programmed to 140/min in order to ensure survival dur-
ing the follow-up time.
Echocardiography
Transthoracic echocardiography (TTE) with assessment
of ventricle size and regurgitation was carried out three
months after pacemaker implantation. In five cases in
which the induction of insufficiency was slower, a fur-
ther TTE was performed four months after pacemaker
implantation. Reference TTEs were obtained during the
week prior to surgery. Control examinations were done
every four weeks after surgery, as well as immediately
before sacrifice. All TTEs were performed blinded by the
same investigator (JA) with a portable GE Vivid-I echo-
cardiography system (GE, Helsinki, Finland).
Study groups and surgical procedure
The sheep were randomly assigned to the individual
groups. For the reference group (Carpentier-Edwards
Classic, Edwards Lifesciences Nordic AB, Finland), CE
annuloplasty rings were implanted into 7 sheep, whereas
13 animals received Medtentia annuloplasty rings
(MAR, Medtentia Oy, Helsinki, Finland) with appropri-
ate dimensions. Seven sheep with MAR were intended
for the direct comparison with animals with CE after
3.6 months, the remaining six MAR animals were
intended for sampling seven, nine or twelve months after
surgery.
Surgical procedures were performed under deep
anesthesia according to standard procedures. All implan-
tations were done by the same team in order to over-
come operator dependency. The sheep were given 5 mg
midazolam and 25 mg/kg bw ketamine hydrochloride i.
m. as premedication. Anesthesia was induced with intra-
venous administration of pentobarbital (12 mg/kg bw)
and fentanyl (7.5 mg/kg bw).
An endotracheal tube was inserted and mechanical
ventilation initiated with tidal volumes set at 8–10 ml/kg
body weight with a 100 ml compensation for dead space,
at rate of 12–15 cycles per minute (Servo 900C; Siemens
Elema AB, Solna, Sweden). The inspired oxygen fraction
(O2-air) was 0.5 and a positive end-expiratory pressure
of 5 cm H2O was applied. End tidal carbon dioxide ten-
sion was monitored with a capnograph (Datex, Helsinki;
Finland). Fentanyl (10 mg/kg/hr) and pentobarbital
(5 mg/kg/hr) were given as continuous infusions formaintenance of anesthesia with a mixture of O2 and
isoflurane. A heating blanket and heater on the cardio
pulmonary by-pass system were used to maintain
normothermia.
Fluid support (Ringer solution) was delivered intraven-
ously as necessary to maintain the systolic blood pres-
sure above 80 mmHg. For continuous monitoring, the
left femoral artery was cannulated for systemic arterial
pressure monitoring. The ECG and oxygenation were
continuously monitored (Datex). After thoracotomy and
administration of heparin (400 IU/kg), the carotid artery
was cannulated with a wire-forced cannula (18 F) for
cardiopulmonary bypass (CPB). The 2-stage venous can-
nula (22 F) was cannulated for the drainage of the ven-
ous return into a cardiotomy reservoir with a pediatric
hollow fiber oxygenator (Jostra, Hirrlingen, Germany). A
Gambro roller pump (Gambro, Lund, Sweden) was used
for CPB with a mixture of heparinized Ringer acetate
(50%) and blood from donor sheep (50%) as the priming
solution. The oxygenator was heated with a water coil
(Heaterâ, Tekamer, Helsinki, Finland). The mitral
annuloplasty ring implantation was performed on-pump
in a beating heart through the left atrial appendix.
The MAR ring was rotated into place starting at the
posterior medial commissurae. The MAR was rotated
360 degrees so that the lower ring of the MAR could
slide onto the ventricular aspect of the annulus, behind
and underneath all chordae. The ring was fixed with a
total of 6 to 10 2–0 pledgeted Ethibond sutures that
were placed in a classical manner to the valve annulus
and through the Dacron cover on the atrial aspect of the
ring. The sutures’ placements were indicated in the sur-
gery protocol of the case report forms. Reference CE
rings were implanted according to the manufacturer’s in-
structions with sutures similar to those used for the
MAR rings.Post-operative care and anticoagulation treatment
After surgery, animals were transported back to the ani-
mal facility for follow-up. Antithrombotic treatment
consisted of 5.000 IU dalteparin s.c. (Fragmin) for the
first 3 days. Diclofenac 75 mg (Voltaren) was given b.i.d.
for the first 5 days after surgery and thereafter as neces-
sary. The antibiotics ceftriaxone (Rocephalin; 1.5 g o.d.)
and tobramycin (Tomycin; 120 mg o.d.) were given
prophylactically for 5 and 3 days, respectively.Sampling
The animals of the CE group and seven animals of the
MAR group were sacrificed after 3.6 ± 0.3 months
follow-up time. Of the remaining MAR group animals,
two were sacrificed at seven, nine, and twelve months
after annuloplasty.
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transported to Helsinki University Hospital or the
Helsinki University Veterinary Medicine Faculty, where
they were sedated with 5 mg midazolam and 25 mg/kg
ketamine hydrochloride i.m. as premedication and eu-
thanized with propofol and an overdose of 40 ml KCl
administered intravenously through a cephalic vein
catheter.
The thoracic cavity was opened and the heart freed by
dissection. After flushing and weighing, the transverse
and longitudinal dimensions were assessed with a ruler.
Blocks of the myocardium were sampled in defined areas
of the ventral and dorsal aspects of the ventricles and
atria. The annuloplasty rings were dissected free and 2 ×
1.5 mm areas of the neointimal layer were harvested
using a scalpel.
Histology
The myocardial samples were embedded for light mi-
croscopy using a standard protocol and stained with
H&E. Cell densities and proliferation were assessed in
the neointimal tissue probes using an anti-PCNA
monoclonal antibody. Quantification was performed
using image analyzing software (Diskus 4.80; Hilgers,
Königswinter, Germany). All sections underwent blinded
quantitation by an independent observer.
Vessel ingrowth and neointimal surface classification
was carried out using an anti-FVIII antibody. Both anti-
bodies were purchased at BD Biosciences Pharmingen
(Heidelberg, Germany). Antibody binding was visualized
via a three-step staining procedure using a biotiny-
lated polyclonal anti-rat Ig-G secondary antibody
(DakoCytomation GmbH, Hamburg, Germany) and the
streptavidin horse-radish peroxidase reaction together
with the DAB detection system.
The dissected, implanted rings were cut into two halves,
one of which was embedded in methylmetacrylate
(MMA), and the other processed for scanning electron
microscopy.
The integration of the implanted rings was evaluated
in polished microsections of MMA-embedded speci-
mens that were cut into 500–800 μm thick sections with
a diamond blade saw and grinded down to 30–70 μm
between rotating glass plates covered with 1200 grade
wet sand paper. Specimens were stained en bloc with
H&E; the sections were documented with a Zeiss
Axiophot microscope (Oberkochen, Germany).
The remaining half of each annuloplasty ring was used
for scanning electron microscopic analysis of the surface
structure. The specimens were fixed in glutaraldehyde,
trimmed, rinsed in phosphate buffer, postfixed in os-
mium tetroxide, rinsed again and placed in acetone solu-
tions of ascending concentrations. After drying, the
rings were mounted on specimen holders and sputteredwith gold in an argon atmosphere prior to scanning elec-
tron microscopy (Philips ESEM XL 30; FEI, Eindhoven,
Netherlands).Statistical analysis
Data were expressed as mean ± standard deviation. One-
way analysis of variance (ANOVA) and Student’s t-test
for unpaired data were used for differences between
groups. The difference was considered statistically sig-
nificant at a level of p < 0.05.Results
Induction of mitral valve insufficiency
The time span needed for induction of a significant mi-
tral valve insufficiency with positive regurgitation was
140 ± 31 days in the animals designated for the MAR
and 117 ± 29 days in the animals designated to the CE
group. The TTEs prior to implantation showed a 2+
level of regurgitation in all but one animal in the MAR
group and one animal in the control group, both of
which had only a 1+ level of regurgitation. Figure 2a
shows the diameters of the left ventricle at the papillary
muscle level, which, in the MAR group had a mean
diameter of 46.7 ± 6.50 mm, comparable to the mean
diameter found in the CE group (43.9 ± 3.39 mm).Implantation time, survival and side effects
All annuloplasty rings were implanted successfully.
Intraoperative water tests revealed competent and tight
valves in all animals. Postoperative recovery was un-
eventful. The time needed for surgery was shorter in the
MAR group (81.9 ± 16.7 min) than in the CE group
(94.2 ± 24.4 min). The perfusion time in the MAR group
(31.8 ± 5 min) was also significantly shorter than in the
CE group (39.4 ± 6.2 min; p = 0.01; Figure 2c). The total
annuloplasty ring implantation time of 12.6 ± 2.6 min in
the MAR group was again significantly shorter than that
needed in the CE group (23.4 ± 4.2 min; p = 0.001;
Figure 2d).
During the follow-up time, one animal in the MAR
test group was found dead 350 days after surgery, shortly
before completion of the one year follow-up. The TTE
in this animal, performed eight weeks after surgery,
showed no regurgitation, whereas moderate-severe re-
gurgitation was seen 6 months after surgery. The left
ventricular end-diastolic diameter was found to have in-
creased to 47 mm. Autopsy revealed – besides the accu-
mulation of 7–8 liters ascites - that the annuloplasty
ring had not caught hold of all chordates, which explains
the reappearance of regurgitation. All other animals
reached the designated end point without complications.
Left ventricle diameters before annuloplasty
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Figure 2 Clinical parameters: Left ventricle diameters assessed by echocardiography before annuloplasty (a) and at the time of
sacrifice (b). c, perfusion time, and d, ring implantation time. Boxplots with 25, 50 and 75th percentiles. Red line =mean.
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TTE prior to tissue sampling revealed no regurgitation
in eleven MAR-test animals and in all control animals.
One test animal showed 2+ level regurgitation and
another animal revealed a mild-moderate regurgitation
one year after surgery. The half-year echocardiographic
examination of this animal showed no signs of valve in-
sufficiency. The end-diastolic left ventricle diameters
(Figure 2b) showed no significant differences between
the MAR group (36.8 ± 5.43 mm) and the CE group
(39.1 ± 4.18 mm; p = 0.147).
Heart weights
The echocardiography data was analogous to the data
on heart weights: after 3.6 months follow up, the CE
group’s mean heart weight (290.0 ± 41.2 g) was compar-
able to that of the MAR group (297.3 ± 46.3 g; p = 0.38).
The same was true when the slightly heavier hearts ofthe long-term follow–up animals (314.6 ± 33.4 g) were
compared to those of the short term animals (p = 0.235).
Macroscopic findings
As shown in Figure 3, all reference group implants were
macroscopically completely covered with connective tis-
sue. The shiny, reflecting surface suggested a reasonable
coverage with endothelial cells. No thrombi were visible.
The atrial side of all Medtentia annuloplasty rings
(Figure 3c and d) also appeared to be completely
covered with whitish, shiny connective tissue as a
neoendocardial layer. The coverage of the ventricular
part of the devices screwed around and caging the
chordae tendineae varied between 5-50%. Some bridges
of subendocardial tissues were visible; the remaining sur-
faces were directly exposed to the circulating blood.
However, in no case were thrombi present. Almost
complete neoendocardial coverage of the ventricular part
a b
c
e
d
f
Figure 3 Annuloplasty rings after sacrifice. a: Edwards-Carpentier annuloplasty ring seen from the atrial side 16 weeks after implantation. b:
shows an example 14 weeks after implantation. Note the macroscopically complete coverage of the device with connective tissue and the
absence of thrombi. c and d show the Medtentia annuloplasty ring 16 weeks after implantation. Note that the ventricular aspect is only partially
covered with endocardial tissue. e and f: Medtentia annuloplasty ring nine months after harvesting from the atrial (e) and ventricular aspect. Note
the partially missing coverage from the ventricular aspect.
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nally, in animals sacrificed after longer follow-up, i.e.
after 7, 9, or 12 months after surgery, a complete
neoendocardial layer was seen on the atrial side together
with limited coverage on the ventricular side (Figure 3e,
f ). Again, in no case were thrombi detectable.
Microscopic findings
The neoendocardial tissue consisted of varying amounts
of subendothelial, fiber-rich connective tissue (Figure 4).
The suture material was well integrated into this tissue,
with some foreign body reaction with multinucleated
and histiocytic cells, and the beginning of small granu-
loma formation being visible in places.
The surface of this newly formed subendocardial tissue
was covered with flatly extended endothelial cells that
were positive for anti-FVIII (Figure 4c, d). Within
the neointima, numerous newly formed vessels werealso seen with a functional endothelium and signs of
perfusion.
The cell packing densities appeared to be different be-
tween the MAR test specimens and the reference group
specimens (Figure 4e, f ). However, morphometrical
assessment of the total cell densities and the PCNA-
antigen positive cells (marker of proliferation) revealed
both in the superficial, subendothelial layer and the
complete tissue layer no significantly different cell and
proliferation densities (data not shown).
Implant integration
Apart from the lower, ventricular part of the MAR-
specimens, practically all annuloplasty rings showed very
good tissue integration (Figure 5). The coating mesh was
fully penetrated by cells and connective tissue in all
specimens of both groups. The foreign body reaction
was comparatively low; in some regions a few foreign
a b
c
e
d
f
Figure 4 Microscopic findings in reference annuloplasty rings (left panel, a, c, e; and Medtentia annuloplasty ring (right panel, b, d, f).
a & b: H&E histology of the newly formed endocardial tissue. Note the significantly thicker layer in the reference sample (bar = 500 μm) than
in the Medtentia annuloplasty ring (bar = 200 μm). c & d: anti-Factor VIII staining reveals a functional endothelium on the surface (arrowheads)
and some subendocardial vessels (arrows). e & f: anti PCNA stains show the fraction of mitotic and postmitotic cells with brownish nuclei.
Bars in b-f = 200 μm.
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sites with greater amounts of granulocytes detectable.
The tissue surrounding the implant was seen to contain
many small vessels.
Scanning electron microscopy
Annuloplasty rings with well endothelialized areas were
mainly seen at protected sites, e.g., under sutures or lat-
eral to the main blood stream (Figure 5c, d). Other parts
showed disrupted or missing endothelium with exposed
collagen fiber bundles, especially at the ring angles.
These findings are consistent with those seen with factor
VIII staining. Qualitative or quantitative differences in
the surface structures of the specimens of the different
groups were not found.
Discussion
The percutaneous management of valvular heart disease
has recently received a great deal of interest and is
considered to be an area of great potential. Innovativetechnologies are now being developed to treat mitral re-
gurgitation [9] in order to meet the need for less com-
plex, reproducible and fast repair techniques which may
be added without further time delay to other heart
procedures. The Medtentia annuloplasty double helix
system may further facilitate the treatment of mitral re-
gurgitation. The aim of this study was to evaluate this
system in an ovine model in comparison to the CE
annuloplasty ring. The superpaced animals used for this
study had significantly enlarged left ventricle diameters
and moderate mitral valve regurgitation. A pilot test on
six animals without annuloplasty revealed that cessation
of the superpacing after induction of mitral valve insuffi-
ciency did not result in spontaneous left ventricle diam-
eter reduction and/or reduction of the regurgitation
within six months observation time (data not shown).
This ovine study has demonstrated that the MAR sys-
tem may be implanted in a significantly shorter time
than the well-proven CE annuloplasty ring enabling a
shortening of additional clamp time in critical or
Figure 5 Implant integration as seen in polished MMA microsections and scanning electron microscopy. Left panel from reference CE
animal 16 weeks after implantation, right images from MAR animal. The coating meshes of both annuloplasty rings are fully penetrated by cells
and connective tissue. The thicknesses of the layer seem to be larger in the reference. In b, the atrial ring is to the right, the ventricular part is not
completely covered with newly formed tissue. d shows details of the sleeve integration. The insets in e and f show the complete endothelial
coverage. Bars in a-d = 500 μm.
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helical construction principle that connects atrial and ven-
tricular surface of the annulus and which restores the valve
geometry by screwing in the double helical device. Con-
trary to other annuloplasty systems the MAR needs stiches
only for for fixation, while in conventional mitral rings the
sewing of the annulus to the ring prosthesis is the active,
more time consuming valve geometry repair step.
The efficacy in terms of functional outcome - as
assessed using echocardiography - proved to be in the
same range as that of the reference group. In one ani-
mal, that was mitral valve competent at the 3 months
follow-up echo, the situation at six and nine months was
seen to have worsened. Autopsy revealed that the ven-
tricular helix part had not correctly encircled all tendin-
ous cords underlining the mode of action of the MAR
system, namely the narrowing and stabilizing of the
valve entrance and guidance of the chordae tendineae.
The latter shows similarities to the concept of the Alfieri
stitch [10].Material biocompatibility and hemocompatibility are
of utmost importance both for tissue integration, avoid-
ance of fibrosis, thrombosis and neoendocardialisation.
Practically all artificial surfaces are capable of activating
platelets and coagulation factors, which may result clin-
ically in thromboembolic complications. The surface
structure of the MAR system with its carbon coating,
however, prevented the formation of microclots in areas
that were not covered with neointimal tissue during the
follow-up. Clinically, no thromboembolic events were
recorded even though the animals received no anticoa-
gulative treatment. Della Barbara et al. [6] reported simi-
lar results in a pyrolytic carbon-coated flexible Sovering
annuloplasty ring.
The atrial sides of both MAR and reference annu-
loplasty rings were always completely integrated with
fibrous tissue covered with a continuous layer of
endothelial cells. The absence of complete coverage in
the ventricular projections may be due to the
hemodynamics: the high pressure and flow gradients as
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the material induce high shear stress that may effectively
prevent cell adhesion. The absence of microthrombi,
however, indicates that this is not a major shortcoming.
The question is, of course, whether this may be extrapo-
lated to the human situation. Several studies have fa-
vored the sheep model as an acceptable animal model
for testing the blood compatibility of devices [11]. In a
study performed in the early 1970s, coagulation values
were compared between mature sheep and normal
human adults [12]. The significant differences found
which were related to the hemostatic system were a
markedly decreased fibrinolytic activity and an increased
platelet number and adhesiveness in sheep. These factors
could be responsible for the increased tendency toward
hypercoagulability.
Conclusion
Both clinical and histological parameters show that the
MAR system is a promising new tool for simple and
effective treatment of mitral regurgitation.
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